Prazosin in hypertension. Clinical studies with special reference to initiation of therapy.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D001581:Benzothiadiazines; D001794:Blood Pressure; D002986:Clinical Trials as Topic; D004232:Diuretics; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D010919:Placebos; D011224:Prazosin / Q000627:therapeutic use*; D011799:Quinazolines / Q000627:therapeutic use*; D049993:Sodium Chloride Symporter Inhibitors / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D001581:Benzothiadiazines; D004232:Diuretics; D010919:Placebos; D011799:Quinazolines; D049993:Sodium Chloride Symporter Inhibitors; D011224:Prazosin